Pre-Defined Subgroups Analyses of TOWER, a Placebo-Controlled Phase 3 Trial of Teriflunomide in Patients with Relapsing Multiple Sclerosis (S41.006)
Authors:
- 12 February 2013
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)